The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients

To assess the pharmacokinetic parameters of vancomycin in Chinese critically ill pediatric patients, children treated with vancomycin, hospitalized in the intensive care unit were included. Samples to determine peak and trough serum concentrations were obtained on the third day of treatment. Half‐life was significantly longer in neonates and showed a decreasing trend in infants and children. In patients aged ≥1 month, AUC24/MIC ≥400 was achieved in 31.8% at the dose of 40 mg/kg/d, and in 48.7% at the dose of 60 mg/kg/d with an assumed MIC of 1 mg/L. Augmented renal clearance (ARC) was present in 27.3% of children, which was associated with higher vancomycin clearance and lower AUC values. A good correlation was observed between trough concentration and AUC24, and the trough concentration that correlated with AUC24 of 400 were varied according to the dosage regimens, 8.42 mg/L for 6‐hintervals, and 6.63 mg/L for 8‐h intervals. To conclude, vancomycin trough concentration that related to the AUC24 of 400 was much lower in critically ill children than that in adults. The dosage of 60 mg/kg/day did not enough for producing AUC24 in the range of 400–600 mg h/L in critically ill children, especially in those with ARC.

[1]  A. Shorr,et al.  Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?-No. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  X. Weng,et al.  Vancomycin in neonatal sepsis: predictive performance of a Chinese neonatal population pharmacokinetic model and clinical efficacy evaluation , 2021, European journal of hospital pharmacy : science and practice.

[3]  J. Qu,et al.  Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Lykkesfeldt,et al.  BCPT policy for experimental and clinical studies , 2020, Basic & clinical pharmacology & toxicology.

[5]  Qiaochuan Li,et al.  Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children , 2020, Journal of clinical pharmacy and therapeutics.

[6]  Yao Liu,et al.  Dynamic Changes of Staphylococcus aureus Susceptibility to Vancomycin, Teicoplanin, and Linezolid in a Central Teaching Hospital in Shanghai, China, 2008–2018 , 2020, Frontiers in Microbiology.

[7]  D. Levine,et al.  Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie , 2020, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  Peninnah Oberdorfer,et al.  Correlation of the vancomycin 24-hour area under the concentration-time curve (AUC24) and trough serum concentration in children with severe infection: A clinical pharmacokinetic study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  N. Curtis,et al.  Vancomycin is commonly under‐dosed in critically ill children and neonates , 2019, British journal of clinical pharmacology.

[10]  S. D. de Wildt,et al.  Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature , 2019, Archives of Disease in Childhood.

[11]  K. Sridharan,et al.  Clinical Pharmacokinetics of Vancomycin in Critically Ill Children , 2019, European Journal of Drug Metabolism and Pharmacokinetics.

[12]  M. Holubar,et al.  Conversion from Vancomycin Trough Concentration–Guided Dosing to Area Under the Curve–Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center , 2019, Pharmacotherapy.

[13]  A. Cook,et al.  Augmented Renal Clearance , 2019, Pharmacotherapy.

[14]  Eric Chang,et al.  Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients , 2018, Pharmacotherapy.

[15]  Chao Chen,et al.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants , 2018, European Journal of Clinical Pharmacology.

[16]  A. Isla,et al.  Augmented Renal Clearance in Critically Ill Patients: A Systematic Review , 2018, Clinical Pharmacokinetics.

[17]  M. H. Ensom,et al.  The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review , 2018, Pediatric Drugs.

[18]  W. Lu,et al.  Population pharmacokinetics of vancomycin in Chinese pediatric patients
. , 2017, International journal of clinical pharmacology and therapeutics.

[19]  V. Stove,et al.  Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? , 2016, The Journal of antimicrobial chemotherapy.

[20]  A. Yu,et al.  Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[21]  P. Gao,et al.  Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function , 2016, Journal of clinical pharmacology.

[22]  J. Pachón,et al.  Optimizing the Clinical Use of Vancomycin , 2016, Antimicrobial Agents and Chemotherapy.

[23]  Yan Liu,et al.  Retrospective Analysis of Vancomycin Nephrotoxicity in Elderly Chinese Patients , 2015, Pharmacology.

[24]  M. Neely,et al.  Innovative approaches to optimizing the delivery of vancomycin in individual patients. , 2014, Advanced drug delivery reviews.

[25]  Tsz-Yin So,et al.  An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents , 2011, International journal of pediatrics.

[26]  J. Roberts,et al.  Implications of augmented renal clearance in critically ill patients , 2011, Nature Reviews Nephrology.

[27]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[30]  R. Sawchuk,et al.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients , 1976, Journal of Pharmacokinetics and Biopharmaceutics.

[31]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword , 2013 .

[32]  D. Paterson,et al.  Augmented Renal Clearance , 2010, Clinical pharmacokinetics.